Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial
Open Access
- 4 December 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 27 (24), 2982-2988
- https://doi.org/10.1093/eurheartj/ehl403
Abstract
Aims A prespecified objective of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) was to assess whether any synergistic effects were apparent between the lipid-lowering and blood-pressure-lowering regimens in preventing cardiovascular events. Methods and results A total of 19 257 hypertensive subjects were randomized to an amlodipine-based regimen or an atenolol-based regimen. Of these, 10 305 subjects with total cholesterol ≤6.5 mmol/L were further randomized to atorvastatin 10 mg daily or placebo. In this analysis, the effects of atorvastatin were compared with placebo on coronary heart disease (CHD), cardiovascular and stroke events in those assigned amlodipine-based and atenolol-based regimens. In the ASCOT lipid-lowering arm (LLA), overall, atorvastatin reduced the relative risk of the primary endpoint of non-fatal myocardial infarction and fatal CHD events by 36% (HR 0.64, CI 0.50-0.83, P=0.0005), total cardiovascular events by 21% (HR 0.79, CI 0.69–0.90, P=0.0005), and stroke by 27% (HR 0.73, CI 0.56–0.96, P=0.024). However, atorvastatin reduced the relative risk of CHD events by 53% (HR 0.47, CI 0.32–0.69, PP=0.025 for heterogeneity). There were no significant differences between the effects of atorvastatin on total cardiovascular events or strokes among those assigned amlodipine (HR 0.73, CI 0.60–0.88, PP: n.s., respectively) or atenolol (HR 0.85, CI 0.71–1.02, P: n.s and HR 0.76, CI 0.53–1.08, P: n.s, respectively). Differences in blood pressure and lipid parameters (placebo corrected) between the two antihypertensive treatment limbs could not account for the differences observed in CHD outcome. Conclusion These findings of an apparent interaction between atorvastatin and an amlodipine-based regimen in the prevention of CHD events are of borderline significance, and hence generate an hypothesis that merits independent evaluation in other trials.This publication has 14 references indexed in Scilit:
- Intermolecular Differences of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Contribute to Distinct Pharmacologic and Pleiotropic ActionsThe American Journal of Cardiology, 2005
- Angiotensin-Converting Enzyme Inhibitors and Calcium Channel Blockers for Coronary Heart Disease and Stroke PreventionHypertension, 2005
- Effect of Antihypertensive Agents on Cardiovascular Events in Patients With Coronary Disease and Normal Blood PressureJAMA, 2004
- Atenolol in hypertension: is it a wise choice?The Lancet, 2004
- MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trialThe Lancet, 2003
- Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialThe Lancet, 2003
- Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesisEuropean Journal of Clinical Investigation, 1994
- Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party.BMJ, 1992
- Retardation of angiographic progression of coronary artery disease by nifedipineThe Lancet, 1990
- MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.BMJ, 1985